Kevin Fonseca

Prof. Dr. Kevin Fonseca


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 December 2018 in Inflammatory Bowel Diseases
Verified
Journal Article
Closed access
PDF file
JDJennifer C C Debruyn
Jennifer C C Debruyn
ISIng Shian Soon
Ing Shian Soon
KFKevin Fonseca
Kevin Fonseca
SFSharon Feng
Sharon Feng
MPMelanie Purtzki
Melanie Purtzki
IWIwona Wrobel
Iwona Wrobel
Data on the serologic status of childhood vaccines, cytomegalovirus (CMV) and Epstein-Barr virus (EBV), are limited in inflammatory bowel disease (IBD). Therefore, we evaluated vaccine coverage and seroprotection, along with CMV and EBV seropositivity, in pediatric IBD. In a cross-sectional study, demographic data, IBD history, vaccine records, and serum for antibodies against measles, mumps, rubella, diphtheria, tetanus, varicella, hepatitis B (HBV), CMV, and EBV were collected from children with IBD. We evaluated potential factors associated with serologic status. Of 156 subjects, vaccine coverage was up to date for age in 93.5% for measles, mumps, rubella, 95.6% for diphtheria, tetanus, pertussis, polio, hemophilus influenza B, 75.8% for HBV, and 93.5% for varicella, including past infection and vaccination. Seroprotection was present in 65.8% for measles, 60.5% for mumps, 79.1% for rubella, 79.5% for diphtheria, 80.8% for tetanus, 70.5% for varicella, and 62.8% for HBV of subjects. Older age at diagnosis was associated with seroprotection among subjects with complete HBV (odds ratio [OR], 1.20; 95% confidence interval [CI], 1.03–1.39) and rubella series (OR, 1.18; 95% CI, 1.02–1.37). Older age at serum collection was associated with seroprotection among subjects with prior varicella vaccination or infection (OR, 1.69; 95% CI, 1.33–2.15). Only 25.2% and 37.8% demonstrated seropositivity to CMV and EBV, respectively. Among subjects on immunosuppressive medications, 75.3% and 62.4% were seronegative for CMV and EBV, respectively. Children with IBD have low serologic protection to childhood vaccines in spite of high vaccine coverage and universal vaccinations. Children with IBD, including a large proportion on immunosuppressive medications, have low seropositivity to CMV and EBV.

3 December 2021 in Vaccines
Verified
Journal Article
Open access
PDF file
CSCatalina Barboza Solis
Catalina Barboza Solis
SNShahnas Najimudeen
Shahnas Najimudeen
ACAna Perez Contreras
Ana Perez Contreras
Ahmed Khaled Abdelrazek AliAhmed Khaled Abdelrazek Ali
Ahmed Khaled Abdelrazek Ali
TJTomy Joseph
Tomy Joseph
FCFaizal Careem
Faizal Careem
In Alberta, infectious laryngotracheitis virus (ILTV) infection is endemic in backyard poultry flocks; however, outbreaks are only sporadically observed in commercial flocks. In addition to ILTV vaccine revertant strains, wild-type strains are among the most common causes of infectious laryngotracheitis (ILT). Given the surge in live attenuated vaccine-related outbreaks, the goal of this study was to assess the efficacy of a recombinant herpesvirus of turkey (rHVT-LT) vaccine against a genotype VI Canadian wild-type ILTV infection. One-day-old specific pathogen-free (SPF) White Leghorn chickens were vaccinated with the rHVT-LT vaccine or mock vaccinated. At three weeks of age, half of the vaccinated and the mock-vaccinated animals were challenged. Throughout the experiment, weights were recorded, and feather tips, cloacal and oropharyngeal swabs were collected for ILTV genome quantification. Blood was collected to isolate peripheral blood mononuclear cells (PBMC) and quantify CD4+ and CD8+ T cells. At 14 dpi, the chickens were euthanized, and respiratory tissues were collected to quantify genome loads and histological examination. Results showed that the vaccine failed to decrease the clinical signs at 6 days post-infection. However, it was able to significantly reduce ILTV shedding through the oropharyngeal route. Overall, rHVT-LT produced a partial protection against genotype VI ILTV infection.

1 May 2019 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Open access
JLJohn C. Lam
John C. Lam
KFKevin Fonseca
Kevin Fonseca
KPKanti Pabbaraju
Kanti Pabbaraju
BMBonnie L. Meatherall
Bonnie L. Meatherall
Clinical syndromes associated with Bartonella quintana infection can be insidious and difficult to diagnose for multiple reasons. Clinically, B. quintana can manifest as asymptomatic bacteremia or with subtle subacute constitutional symptoms. Second, it is a fastidious organism that is difficult to identify using traditional culture methods. Last, the body lice vector of B. quintana transmission is likely not uncommon in most patients affected, who are homeless and of low socioeconomic status. Therefore, barriers in seeking medical care and financial constraints for medications are important considerations. The mainstay of literature surrounding B. quintana endocarditis is from Europe and the developing nations. Herein, we describe a case of native valve endocarditis secondary to B. quintana in a homeless male with preexisting valvular disease and undertake a comprehensive literature review of documented B. quintana endocarditis in North America.

1 August 2008 in Antiviral Research
Verified
Journal Article
Closed access
KPKanti Pabbaraju
Kanti Pabbaraju
KHKevin C.Y. Ho
Kevin C.Y. Ho
SWSallene Wong
Sallene Wong
SSSandy Shokoples
Sandy Shokoples
XPXiaoli L. Pang
Xiaoli L. Pang
JFJulie D. Fox
Julie D. Fox

1 January 2015 in Vaccine
Verified
Journal Article
Closed access
FLFlorence Y. Lai
Florence Y. Lai
DDDouglas C. Dover
Douglas C. Dover
BLBonita Lee
Bonita Lee
KFKevin Fonseca
Kevin Fonseca
NSNatalia Solomon
Natalia Solomon
CCCarmen Lynn Charlton
Carmen Lynn Charlton

12 November 2020 in Viruses
Verified
Journal Article
Open access
PDF file
ACAna Perez Contreras
Ana Perez Contreras
FMFrank Van der Meer
Frank Van der Meer
SCSylvia Checkley
Sylvia Checkley
TJTomy Joseph
Tomy Joseph
RKRobin King
Robin King
FCFaizal Careem
Faizal Careem
Infectious laryngotracheitis virus (ILTV) is a herpes virus that causes an acute respiratory disease of poultry known as infectious laryngotracheitis (ILT). Chicken embryo origin (CEO) and tissue culture origin (TCO) live attenuated vaccines are routinely used for the control of ILT. However, vaccine virus is known to revert to virulence, and it has been recently shown that ILT field viral strains can undergo recombination with vaccinal ILTV and such recombinant ILT viruses possess greater transmission and pathogenicity potential. Based on complete or partial genes of the ILTV genome, few studies genotyped ILTV strains circulating in Canada, and so far, information is scarce on whole-genome sequencing or the presence of recombination in Canadian ILTV isolates. The objective of this study was to genetically characterize the 14 ILTV isolates that originated from three provinces in Canada (Alberta, British Columbia and Quebec). To this end, a phylogenetic analysis of 50 ILTV complete genome sequences, including 14 sequences of Canadian origin, was carried out. Additional phylogenetic analysis of the unique long, unique short and inverted repeat regions of the ILTV genome was also performed. We observed that 71%, 21% and 7% of the ILTV isolates were categorized as CEO revertant, wild-type and TCO vaccine-related, respectively. The sequences were also analyzed for potential recombination events, which included evidence in the British Columbia ILTV isolate. This event involved two ILTV vaccine (CEO) strains as parental strains. Recombination analysis also identified that one ILTV isolate from Alberta as a potential parental strain for a United States origin ILTV isolate. The positions of the possible recombination breakpoints were identified. These results indicate that the ILTV wild-type strains can recombine with vaccinal strains complicating vaccine-mediated control of ILT. Further studies on the pathogenicity of these ILTV strains, including the recombinant ILTV isolate are currently ongoing.